Company news

Corcept Therapeutics Incorporated news in 2025

Corcept Therapeutics Incorporated's news releases, calls and decks from 2025, newest first.

View company

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

December 30, 2025

Alger Russell Innovation Index Updates for Fourth Quarter 2025

December 15, 2025

Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

November 3, 2025

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

October 27, 2025

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

October 18, 2025

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

October 13, 2025

Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics

October 1, 2025

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025

September 21, 2025

Alger Russell Innovation Index Updates for Third Quarter 2025

September 15, 2025

FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

September 9, 2025

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

July 13, 2025

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care

June 22, 2025

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

June 4, 2025

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

June 1, 2025

Corcept Therapeutics announces first quarter financial results and provides corporate update

May 4, 2025

Corcept Therapeutics to announce first quarter financial results, provide corporate update and host conference call

April 27, 2025

Corcept to present late-breaking data from pivotal phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer at ASCO 2025

April 22, 2025

Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

April 20, 2025

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

April 6, 2025

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

March 30, 2025

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

March 9, 2025

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

March 2, 2025

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

February 25, 2025

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

February 11, 2025

Calls in 2025

Decks in 2025